Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
PharmAthene, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
42224H104
(CUSIP Number)
September 28, 2011**
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o |
Rule 13d-1(b)
|
| x |
Rule 13d-1(c)
|
| o |
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
** On September 28, 2011, HealthCare Ventures VII, L.P. distributed to its general and limited partners the shares of PharmAthene, Inc. Common Stock, $.0001 par value per share, owned by it.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 42224H104
|
13G
|
Page 2 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
HealthCare Ventures VII, L.P.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
280,998
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
PN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 3 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
HealthCare Partners VII, L.P.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
280,998
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
PN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 4 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
James H. Cavanaugh, Ph.D.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
77,816
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
77,816
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
358,814
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.7%
|
||
|
12
|
TYPE OF REPORTING PERSON*
IN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 5 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Christopher Mirabelli, Ph.D.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
5,361
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
5,361
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
286,359
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
IN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 6 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Harold R. Werner
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
7,045
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
7,045
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
288,043
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
IN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 7 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
John W. Littlechild
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
5,723
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
5,723
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
286,721
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
IN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 8 of 14 Pages
|
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Augustine Lawlor
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) o
(b) o
|
||
|
3
|
SEC USE ONLY
|
||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
|
NUMBER OF
|
5
|
SOLE VOTING POWER
3,538
|
|
|
SHARES
BENEFICIALLY
OWNED BY
|
6
|
SHARED VOTING POWER
280,998
|
|
|
EACH
REPORTING
PERSON
|
7
|
SOLE DISPOSITIVE POWER
3,538
|
|
|
WITH
|
8
|
SHARED DISPOSITIVE POWER
280,998
|
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
284,536
|
||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
|
||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
|
||
|
12
|
TYPE OF REPORTING PERSON*
IN
|
||
|
CUSIP No. 42224H104
|
13G
|
Page 9 of 14 Pages
|
Item 1.
|
(a)
|
Name of Issuer
|
PharmAthene, Inc.
|
(b)
|
Address of Issuer’s Principal Executive Offices
|
|
|
One Park Place, Suite 450
|
|
|
Annapolis, MD 21401
|
Item 2.
|
(a)
|
Name of Person Filing
|
|
|
HealthCare Ventures VII, L.P. (“HCVVII”)
|
|
|
HealthCare Partners VII, L.P. (“HCPVII”)
|
|
|
James H. Cavanaugh, Ph.D. (“Cavanaugh”)
|
|
|
Christopher Mirabelli, Ph.D. (“Mirabelli”)
|
|
|
Harold R. Werner (“Werner”)
|
|
|
John W. Littlechild (“Littlechild”)
|
|
|
Augustine Lawlor (“Lawlor”)
|
|
|
See attached Exhibit A, which is a copy of their agreement in writing to file this statement on behalf of each of them. 1
|
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
|
|
The business address for each of HCVVII, HCPVII, Drs. Cavanaugh and Mirabelli and and Messrs. Werner, Littlechild and Lawlor is 55 Cambridge Parkway, Suite 301, Cambridge, Massachusetts 02142.
|
|
(c)
|
Citizenship
|
|
|
HCVVII and HCPVII are limited partnerships organized under the laws of the State of Delaware. Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild, and Lawlor are each United States citizens.
|
1 Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor are the General Partners of HCPVII. HCPVII is the General Partner of HCVVII, the record holder of the securities.
|
CUSIP No. 42224H104
|
13G
|
Page 10 of 14 Pages
|
|
(d)
|
Title of Class of Securities
|
|
|
Common Stock, $0.0001 par value per share (the “Common Stock”)
|
|
(e)
|
CUSIP Number
|
42224H104
|
Item 3.
|
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
NOT APPLICABLE.
|
|
(a)
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
(b)
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
(c)
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
(d)
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
|
|
|
(e)
|
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
(f)
|
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
(g)
|
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
|
(h)
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
(i)
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
(j)
|
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
|
|
Item 4.
|
Ownership.
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
(a)
|
Amount beneficially owned:
|
|
|
As of September 28, 2011:
|
|
|
(A) Each of HCVVII and HCPVII beneficially owns immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII.
|
|
|
(B) Dr. Cavanaugh beneficially owns 358,814 shares of the Issuer’s Common Stock, consisting of (i) 5,057 shares of the Issuer’s Common Stock owned by him; (ii) immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII; and (iii) immediately exercisable options to purchase an aggregate of 72,759 shares of the Issuer’s Common Stock owned by him.
|
|
CUSIP No. 42224H104
|
13G
|
Page 11 of 14 Pages
|
|
|
(C) Dr. Mirabelli beneficially owns 286,359 shares of the Issuer’s Common Stock, consisting of (i) 5,361 shares of the Issuer’s Common Stock owned by him; and (ii) immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII.
|
|
|
(D) Mr. Werner beneficially owns 288,043 shares of the Issuer’s Common Stock, consisting of (i) 55 shares of the Issuer’s Common Stock owned by him; (ii) immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII; (iii) immediately exercisable options to purchase an aggregate of 1,655 shares of the Issuer’s Common Stock owned by him; and (iv) 5,335 shares of the Issuer’s Common Stock owned by the Werner Family Investment Limited Partnership (the “Werner Family Partnership”).
|
|
|
(E) Mr. Littlechild beneficially owns 286,721 shares of the Issuer’s Common Stock, consisting of (i) 5,723 shares of the Issuer’s Common Stock owned by him; and (ii) immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII.
|
|
|
(F) Mr. Lawlor beneficially owns 284,536 shares of the Issuer’s Common Stock, consisting of (i) 3,538 shares of the Issuer’s Common Stock owned by him; and (ii) immediately exercisable warrants to purchase an aggregate of 280,998 shares of the Issuer’s Common Stock owned by HCVVII.
|
|
(b)
|
Percent of class: (Computed in accordance with Rule 13d-3(d)(i) and based on (i) 48,232,101 shares of the Issuer’s Common Stock issued and outstanding as of August 4, 2011, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2011 for the period ended June 30, 2011; (ii) 280,998 shares of the Issuer’s Common Stock underlying the warrants owned by HCVVII; (iii) in the case of Dr. Cavanaugh, 72,759 shares of the Issuer’s Common Stock underlying currently exercisable options owned by him; and (iv) in the case of Mr. Werner, 1,655 shares of the Issuer’s Common Stock underlying currently exercisable options owned by him.)
|
|
|
As of September 28, 2011:
|
|
|
(A) the 280,998 shares of the Issuer’s Common Stock beneficially owned by HCVVII, HCPVII, constituted 0.6% of the shares outstanding.
|
|
|
(B) the 358,814 shares of the Issuer’s Common Stock beneficially owned by Dr. Cavanaugh constituted 0.7% of the shares outstanding.
|
|
|
(C) the 286,359 shares of the Issuer’s Common Stock beneficially owned by Dr. Mirabelli constituted 0.6% of the shares outstanding.
|
|
|
(D) the 288,043 shares of the Issuer’s Common Stock beneficially owned by Mr. Werner constituted 0.6% of the shares outstanding.
|
|
|
(E) the 286,721 shares of the Issuer’s Common Stock beneficially owned by Mr. Littlechild constituted 0.6% of the shares outstanding.
|
|
CUSIP No. 42224H104
|
13G
|
Page 12 of 14 Pages
|
|
|
(F) the 284,536 shares of the Issuer’s Common Stock beneficially owned by Mr. Lawlor constituted 0.6% of the shares outstanding.
|
|
(c)
|
Number of shares as to which the person has:
|
|
(i)
|
Sole power to vote or to direct the vote –
|
Dr. Cavanaugh has the sole power to vote or to direct the vote of the 5,057 shares of the Issuer’s Common Stock owned by him and the 72,759 shares of the Issuer’s Common Stock issuable upon exercise of the options owned by him.
Dr. Mirabelli has the sole power to vote or to direct the vote of the 5,361 shares of the Issuer’s Common Stock owned by him.
Mr. Werner has the sole power to vote or to direct the vote of the 5,390 shares of the Issuer’s Common Stock owned by him and by the Werner Family Partnership and the 1,655 shares of the Issuer’s Common Stock issuable upon exercise of options owned by him.
Mr. Littlechild has the sole power to vote or to direct the vote of the 5,723 shares of the Issuer’s Common Stock owned by him.
Mr. Lawlor has the sole power to vote or to direct the vote of the 3,538 shares of the Issuer’s Common Stock directly by him.
|
|
(ii)
|
Shared power to vote or to direct the vote –
|
|
|
HCVVII, HCPVII, Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor share the power to vote or direct the vote of the 280,998 shares of the Issuer’s Common Stock issuable upon exercise of the warrants owned by HCVVII.
|
|
(iii)
|
Sole power to dispose or to direct the disposition of –
|
Dr. Cavanaugh has the sole power to dispose of or to direct the disposition of the 5,057 shares of the Issuer’s Common Stock owned by him and the 72,759 shares of the Issuer’s Common Stock issuable upon exercise of the options owned by him.
Dr. Mirabelli has the sole power to dispose of or to direct the disposition of the 5,361 shares of the Issuer’s Common Stock owned by him.
Mr. Werner has the sole power to dispose of or to direct the disposition of the 5,390 shares of the Issuer’s Common Stock owned by him and by the Werner Family Partnership and the 1,655 shares of the Issuer’s Common Stock issuable upon exercise of options owned by him.
Mr. Littlechild has the sole power to dispose of or to direct the disposition of the 5,723 shares of the Issuer’s Common Stock owned by him.
|
CUSIP No. 42224H104
|
13G
|
Page 13 of 14 Pages
|
Mr. Lawlor has the sole power to dispose of or to direct the disposition of the 3,538 shares of the Issuer’s Common Stock directly by him.
|
(iv)
|
Shared power to dispose or to direct the disposition of –
|
|
|
HCVVII, HCPVII, Drs. Cavanaugh and Mirabelli and Messrs. Werner, Littlechild and Lawlor share the power to dispose of or direct the disposition of the 280,998 shares of the Issuer’s Common Stock issuable upon exercise of the warrants owned by HCVVII.
|
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not Applicable
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
|
Not Applicable
|
Item 8.
|
Identification and Classification of Members of the Group.
|
Not Applicable
|
Item 9.
|
Notice of Dissolution of Group.
|
Not Applicable
|
Item 10.
|
Certification
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
CUSIP No. 42224H104
|
13G
|
Page 14 of 14 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
October 4, 2011
|
HealthCare Ventures VII, L.P.
|
||
|
By: its General Partner, HealthCare Partners VII, L.P.
|
|||
|
By:
|
/s/ Jeffrey Steinberg
|
||
|
Jeffrey Steinberg, Administrative Partner
|
|||
|
October 4, 2011
|
HealthCare Partners VII, L.P.
|
||
|
By:
|
/s/ Jeffrey Steinberg
|
||
|
Jeffrey Steinberg, Administrative Partner
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffery Steinberg, Attorney-in-Fact
|
|||
|
James H. Cavanaugh, Ph.D.
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Christopher Mirabelli, Ph.D.
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Harold R. Werner
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
John W. Littlechild
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Augustine Lawlor
|
|||
CUSIP No. 42224H104
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G
The undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13G and any future amendments thereto reporting each of the undersigned’s ownership of securities of PharmAthene, Inc. and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned.
|
October 4, 2011
|
HealthCare Ventures VII, L.P.
|
||
|
By: its General Partner, HealthCare Partners VII, L.P.
|
|||
|
By:
|
/s/ Jeffrey Steinberg
|
||
|
Jeffrey Steinberg, Administrative Partner
|
|||
|
October 4, 2011
|
HealthCare Partners VII, L.P.
|
||
|
By:
|
/s/ Jeffrey Steinberg
|
||
|
Jeffrey Steinberg, Administrative Partner
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffery Steinberg, Attorney-in-Fact
|
|||
|
James H. Cavanaugh, Ph.D.
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Christopher Mirabelli, Ph.D.
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Harold R. Werner
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
John W. Littlechild
|
|||
|
October 4, 2011
|
|||
|
/s/Jeffrey Steinberg, Attorney-in-Fact
|
|||
|
Augustine Lawlor
|
|||